A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Latest Information Update: 28 Oct 2020
Price :
$35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seagen
- 28 Jun 2017 This trial has been completed in Czech Republic (end date: 1 May 2017).
- 26 May 2017 This trial has been completed in Spain, according to European Clinical Trials Database.
- 12 Jan 2017 This trial has been suspenden in Spain as per European Clinical Trials Database record.